Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Agios Pharmaceuticals, Inc.

Latest From Agios Pharmaceuticals, Inc.

Agios Shows Pyrukynd Can Reduce Transfusions In Thalassemia

Having already posted Phase III success in non-transfusion dependent patients, Agios’s Pyrukynd now has shown the ability to reduce transfusions in alpha and beta thalassemia patients.

Clinical Trials Business Strategies

Agios Extends Cash Runway With $905m Royalty Pharma Deal

Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.

Deals Cancer

EHA Preview: Agios Takes Spotlight In Thalassemia

The company expects to have data from transfusion-dependent and non-transfusion dependent patients this year, with a potential expanded US approval in 2025 for Pyrukynd.

Companies Clinical Trials

Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline

Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.

Market Intelligence Market Snapshot
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals